Summary of Key Information:
Reporting Period: Quarter ended 30 June 2026 (Q1 FY27)
Nature of Filing / Announcement: Outcome of Board Meeting - Financial Results and Dividend Declaration
Audit Opinion:
Clean opinion - Limited review conducted by B S R and Co Chartered Accountants. No material misstatements identified.
Key Financial Highlights [₹ in Lakhs]:
Standalone Results:
Revenue from Operations: ₹10,568.33 (Q1 FY27) vs ₹8,017.42 (Q1 FY26) - 32% YoY increase
Total Income: ₹11,508.36 (Q1 FY27) vs ₹8,679.38 (Q1 FY26) - 33% YoY increase
Net Profit: ₹3,382.85 (Q1 FY27) vs ₹2,520.49 (Q1 FY26) - 34% YoY increase
EPS: ₹3.00 (Basic and Diluted) for Q1 FY27
Other Equity: ₹77,471.43 (as of 31 March 2026)
Consolidated Results:
Revenue from Operations: ₹15,827.05 (Q1 FY27) vs ₹12,491.75 (Q1 FY26) - 27% YoY increase
Total Income: Not separately specified
Net Profit: ₹4,058.69 (Q1 FY27) vs ₹3,126.92 (Q1 FY26) - 30% YoY increase
EPS: ₹3.59 (Basic) for Q1 FY27
Other Equity: Not specified
Segment-wise Performance [₹ in Lakhs]:
The Group operates in two segments:
Pharmaceutical, Food and Nutrition Segment:
External Revenue: ₹10,841.37 (Q1 FY27) vs ₹8,208.68 (Q1 FY26)
Segment Result: ₹4,002.45 (Q1 FY27) vs ₹2,657.21 (Q1 FY26)
Segment Assets: ₹78,691.31 (as of 30 June 2026)
Speciality Ingredients Segment:
External Revenue: ₹4,985.68 (Q1 FY27) vs ₹4,193.07 (Q1 FY26)
Segment Result: ₹1,088.60 (Q1 FY27) vs ₹1,405.07 (Q1 FY26)
Segment Assets: ₹46,307.39 (as of 30 June 2026)
Corporate Actions:
Interim Dividend: ₹3.59 per equity share of face value ₹1 each for FY27
Other Significant Information:
IPO Proceeds Utilization:
Gross Proceeds: ₹9,500.00 lakhs
Less: Estimated offer expenses borne by Company: ₹666.41 lakhs
Net Proceeds: ₹8,833.59 lakhs
Utilization as of 30 June 2026:
- Capital expenditure for Nandesari Facility: ₹35.77 lakhs utilized, ₹7,545.63 lakhs unutilized (kept as term deposits)
- General corporate purposes: ₹1,252.19 lakhs fully utilized
- Total utilized: ₹1,287.96 lakhs
- Total unutilized: ₹7,545.63 lakhs
Acquisition Update:
The Group completed final purchase price allocation for its acquisition of 85% equity interest in Nutrition Supplier & Services (Ireland) Limited (NSS) for ₹12,857.63 lakhs. The acquisition was completed on 22 May 2025, and NSS became a step-down subsidiary. Goodwill has been recognized in the unaudited consolidated financial results.